Back to mobile site

Vertex Pharma (VRTX): Solid Beat And No Guidance Until PDUFA Date, PT To $197 - BofA

February 1, 2018 6:51 AM EST Send to a Friend
BofA/Merrill Lynch analyst, Ying Huang, reiterated his Buy rating on shares of Vertex (NASDAQ: VRTX) and raised his price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login